| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 43.1 | 0.0 | 0.0 |
| Total income | 43.1 | 0.0 | 0.0 |
| Profit before exceptional items & tax | 16.3 | 0.0 | 0.0 |
| Profit before tax | 16.3 | 0.0 | 0.0 |
| Net profit | 11.9 | 0.0 | 0.0 |
| Operating margin | 37.8% | 0.0% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
NSE results filing, NSE: BMLL. Figures extracted from the filing.
Bio Medica Laboratories Ltd: key numbers
- Share price
- ₹164.50
- Market cap
- ₹206.9 Cr
- Revenue (annual)
- ₹43.09 Cr
- Net profit (annual)
- ₹11.89 Cr
- P/E (TTM)
- 17.4×Sector 50.4×
- Promoter holding
- 67.70%
- FII holding
- 0.29%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bio Medica Laboratories Ltd
All →Bio Medica Laboratories Annual General Meeting
Bio Medica Laboratories Limited has issued a notice for its 11th Annual General Meeting, scheduled for September 28, 2026, to conduct ordinary and special business.
Bio Medica Laboratories Management Change
Bio Medica Laboratories Limited has appointed M/s. Vishakha Agrawal & Associates as the Secretarial Auditor of the company effective September 2, 2026.
Bio Medica Laboratories Other Announcement
Bio Medica Laboratories Limited has appointed M/s. Vishakha Agrawal & Associates as the Secretarial Auditor of the Company, effective from September 02, 2026.
Bio Medica Laboratories Board Meeting Outcome
Bio Medica Laboratories announced the outcome of its board meeting, approving the 11th AGM notice, book closure dates, and the appointment of a Secretarial Auditor.